Lomond Therapeutics Holdings, Inc.
Clinical trials sponsored by Lomond Therapeutics Holdings, Inc., explained in plain language.
-
New hope for Hard-to-Treat leukemia? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new oral drug, ZE46-0134, in 150 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. The study focuses on people with specific gene changes (FLT3 or spliceosome mutations). The main goals are to check safe…
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill ZE50-0134 takes on Hard-to-Treat leukemia and lymphoma
Disease control Recruiting nowThis early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC